Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

AIM: Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study (NCT01765790) assessed the safety, tolerability, pharmacokinetics and antitumour activity of imalumab, an oxMIF inhibitor, in patients with advanced c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444762/
https://ncbi.nlm.nih.gov/pubmed/32207164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14289
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky